Repligen Corporation's (RGEN) stock is soaring 9.47% in the pre-market trading session on Thursday, defying expectations after the company reported mixed results for the fourth quarter of 2024.
While Repligen's quarterly sales of $167.55 million narrowly missed analysts' consensus estimate of $167.67 million, the bioprocessing company's adjusted earnings per share (EPS) of $0.44 beat the expected $0.41, representing a 7.32% surprise. Despite a slight year-over-year decline of 8.33% in EPS, the company's better-than-expected earnings performance appears to be driving the significant pre-market rally in its shares.
Repligen's ability to deliver strong earnings in the face of moderate revenue growth underscores its operational efficiency and cost control measures. As the company continues to expand its bioprocessing product portfolio and capitalize on growing demand in the biopharmaceutical industry, investors are likely anticipating sustained profitability, fueling the surge in its stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.